Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display

94P - Does hyperprogressive disease predict poor survival?

Date

08 Dec 2022

Session

Poster Display

Presenters

Gulin Alkan

Citation

Annals of Oncology (2022) 16 (suppl_1): 100102-100102. 10.1016/iotech/iotech100102

Authors

G. Alkan1, N. Senturk Oztas1, E. Degerli1, H. Turna1, M. Özgüroglu2

Author affiliations

  • 1 Istanbul University - Cerrahpasa Faculty of Medicine, Istanbul/TR
  • 2 Istanbul University Cerrahpasa, Cerrahpasa Faculty of Medicine, Istanbul/TR

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 94P

Background

Hyperprogressive disease (HPD) is a new phenomenon developing in the era of immune checkpoint inhibitor (ICI) therapy. HPD is characterized by an unexpected and fast progression in tumor volume and poor survival.There is no standardized definition for HPD and clinicopathological variables associated with HPD are unclear. Herein, we assessed incidence and factors predictive of HPD in patients terated with ICIs.

Methods

We retrospectively analysed patients with advanced cancer treated with ICI at Cerrahpasa Medical Faculty Clinical Trial Unit between 2014-2021. We used the Lo Russo’s adopted criteria combined clinical and radiologic parameters for the definition of HPD. All patients who underwent their first tumor evaluation according to RECIST1.1 were included.

Results

Of 155 patients,147 were eligible for analysis. The median age was 61 and 83% were male. The cancer types were; 67,3% lung, 12,9% bladder, 9,5% gastric, 5,4% colon and 4,8% renal cell carcinoma. 59,9% patients were treatment naive and others had one or more lines of chemotherapy. There were 124 patients (84%) who received a single-agent ICI as PD-1 or PD-L1 inhibitors. 23 (16%) patients were treated with combination ICI with anti VEGF, TKI or other ICIs. The median duration of follow-up was 15,6 months. Incidence of HPD was 12,9%. Patients with progressive disease (PD) without HPD were the 20,4%. The median overall survival (mOS) was 3,0 months for HPD patients and 23,1 months for non-HPD patients (p <.001). The mOS for HPD and PD without HPD was 3,0 vs 7,7 months respectively (p <.001). In the univariate analysis (HPD vs non-HPD group) baseline sum of diameters of the lesions (p=0.040) and the baseline high LDH levels (p=0.040) were associated with HPD.

Conclusions

With increased use of ICIs, early recognition of HPD that is predicting very poor survival, will provide insight for the physicians in the management of cancer patients.

Legal entity responsible for the study

G. Alkan.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.